According to NovoCare, Wegovy’s manufacturer, people with private or commercial insurance can pay as little as $0 per 28-day supply of the medication. People without insurance can expect to pay ...

In the second quarter, increased supply led ... as seen in the chart below. Estimates for Lilly’s 2024 earnings have declined from $13.50 to $13.19 per share over the past 30 days.

Eli Lilly and Company LLY announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival Novo Nordisk’s NVO Wegovy ... impacted by supply and channel ...